German biotechnology company BioNTech SE and Chinese pharmaceutical company Shanghai Fosun Pharmaceutical (Fosun) will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China, Reuters news agency reported on Wednesday.
In a statement, BioNTech and Fosun said that this vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Centre for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China.
In addition, BioNTech is working with US pharmaceutical company Pfizer Inc on the vaccine.
The companies had said last week they were hoping to win approval in the US and Europe this year, after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval